Selpercatinib for the treatment of patients with advanced RET fusion positive non-small-cell lung cancer

19 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...

Read more →

Durvalumab in combination with etoposide phosphate and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small-cell lung cancer

19 February 2025 - NICE has published final evidence-based recommendations on durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin ...

Read more →

Olaparib for the treatment of patients with advanced, BRCA mutation positive, HER2 negative breast cancer after chemotherapy

12 February 2025 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) for the treatment of ...

Read more →

Selpercatinib for the treatment of patients with advanced thyroid cancer with a RET alteration untreated with a targeted cancer medicine

12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...

Read more →

Selpercatinib for the treatment of patients with advanced thyroid cancer with a RET alteration after treatment with a targeted cancer medicine (final guidance)

12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...

Read more →

Ganaxolone for the treatment of patients 2 years of age and older with seizures caused by CDKL5 deficiency disorder

12 February 2025 - NICE has published final evidence-based recommendations on the use of ganaxolone (Ztalmy) for the treatment of ...

Read more →

February 2025 decisions

10 February 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...

Read more →

Pembrolizumab for adjuvant treatment of patients with resected non-small-cell lung cancer (final guidance)

5 February 2025 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adjuvant treatment ...

Read more →

Elacestrant dihydrochloride for the treatment of patients with advanced, oestrogen receptor positive, HER2 negative breast cancer with an ESR1 mutation after endocrine treatment (final guidance)

5 February 2025 - Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation ...

Read more →

Outcomes from the December 2024 PBAC meeting

31 January 2025 - Recommendations made by the PBAC in December 2024 relating to the listing of medicines on the PBS ...

Read more →

Santhera’s Duchenne muscular dystrophy drug Agamree accepted by SMC

16 January 2025 - The rare muscle wasting disorder affects approximately 2,500 males in the UK at any one time. ...

Read more →

January 2025 decisions

13 January 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...

Read more →

Vadadustat for the treatment of adults with symptomatic anaemia on dialysis for chronic kidney disease

23 January 2025 - NICE has published final evidence-based recommendations on the use of vadadustat (Vafseo) for the treatment of ...

Read more →

NICE has made six times more lung cancer treatment recommendations over the past ten years than in the previous decade

21 January 2025 - We have also recommended osimertinib for routine use on the NHS today. ...

Read more →

Erdafitinib for the treatment of patients with metastatic or unresectable FGFR altered urothelial cancer

9 January 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →